Almost 50 more genes have been flagged as being linked to Alzheimer’s, along with changes in activity in crucial cells that disappear as dementia progresses

Big pharma plans Phase 2 Alzheimer’s trial of Vigil’s oral TREM2 agonist designed to convert microglia into their neuroprotective state. Pharma giant Sanofi has completed its acquisition of Vigil Neuroscience, aiming to bolster its early-stage neurology portfolio with assets focused on neurodegenera…

Company targets metabolic imbalances in the brain to treat neurodegenerative diseases including ALS and Alzheimer’s. US biotech Leal Therapeutics has secured $30 million in Series A funding to advance its pipeline of neuro-metabolic therapies, with a focus on treating neurodegenerative and neuropsyc…

Barcelona-based INBRAIN Neuroelectronics, a company developing graphene-based brain-computer interface therapeutics (BCI-Tx), has entered into a know-how collaboration agreement with Mayo Clinic to accelerate development and commercialization of its precision BCI-Tx platform for neurological disorde…

Neuropixels Opto is a single brain probe combining electrophysiology and optogenetics that simultaneously records and controls neurons deep in the brain, enabling unprecedented insights into neural circuits and brain function. The post Neuropixels Opto Integrates Electrophysiology and Optogenetics t…

Jupiter Neurosciences starts enrolling patients in a mid-stage study for JOTROL, an oral candidate targeting Parkinson’s at its roots. Targeting Parkinson’s at its roots sounds straightforward in theory, but in practice, it has defeated scientists for decades. Most treatments available today help pa…

VectorY Therapeutics and Shape Therapeutics have entered an option and license agreement to advance vectorized antibody therapies for neurodegenerative diseases, according to the company. The deal grants VectorY exclusive rights to evaluate Shape’s SHP-DB1, a deep-brain-penetrating AAV5-derived caps…

OpenAI founder’s Merge Labs startup seeks to develop ‘less invasive’ options for brain-computer interface technology. A significant new player appears set to emerge in the increasingly competitive landscape of brain–computer interfaces. OpenAI founder Sam Altman is reportedly behind a new venture ca…

Aspen Neuroscience has launched Cohort 3 of its ASPIRO Phase 1/2a clinical trial for ANPD001, its autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson’s disease, the company announced. Cohort 3 marks the first use of Aspen’s commercial formulation of ANPD001, which the compa…

Clene Inc. has presented clinical results from its REPAIR trials at the ECTRIMS 2025 meeting in Barcelona, asserting that treatment with its investigational therapy CNM-Au8 improved brain energy metabolism in patients with multiple sclerosis (MS). According to the company, combined Phase 2 data acro…

Inflammatory pathways involving microglia, astrocytes, and cytokine signaling are widely implicated in disorders including Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, and traumatic brain injury. Yet despite significant investment in anti-inflammatory therapies, clinical succes…

NeuroSense Therapeutics Ltd. has reported that its experimental Alzheimer’s therapy PrimeC produced statistically significant reductions in multiple microRNAs associated with Alzheimer’s disease, according to the company. In plasma samples from its Phase 2b PARADIGM trial, PrimeC significantly reduc…

AI-generated predictive biomarkers enable early detection and precision intervention in Parkinson’s and dementia. British healthtech startup Kneu Health has raised $5.6 million in seed funding to advance its smartphone platform designed to detect and track neurodegenerative decline. Building on rese…

Cumulus announced that it presented multiple studies at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam. According to the company, one poster showcased interim data from …

McGill study shows digital cognitive exercises can rejuvenate brain chemistry linked to memory and attention. For years, the idea that a digital ‘brain game’ could do more than mildly entertain or pass the time between Wordle rounds has been met with polite skepticism. Yet a new study fr…

Cortechs.ai has acquired intellectual property from ZepMed, LLC, including its patented CT imaging technologies and its key product, NeuroAlign CT™, the company said. The acquisition bolsters Cortechs.ai’s neuroimaging portfolio and strengthens its position in AI-powered radiology solutions, the com…